CNTX - Company ID 0001842952
The table below shows Context Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$11.43M | -$5.03M | -$4.36M | -$5.73M | -$3.82M | -$1.72M |
| Capital expenditure | $37.26K | $33.95K | $0.00 | $0.00 | $35.00K | $0.00 |
| Investing cash flow | -$37.26K | -$33.95K | $0.00 | $0.00 | -$35.00K | $0.00 |
| Dividends paid | - | - | - | - |
Context Therapeutics Inc. reported operating cash flow of -$26.39M for fiscal year 2025. That is down 81.3% from -$14.56M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$1.03M (FY 2020) to -$26.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $0.00 | -$15.27K | $0.00 | $0.00 | -$102.07K | $3.03M |